Overexpression of TC2N is associated with poor prognosis in gastric cancer.

Tac2-N (TC2N) is a tandem C2 domain-containing protein, acting as a novel oncogene or suppressor in different kinds of cancers. However, the status of expression and its significance in gastric cancer (GC) is still unclear. The present study is aimed to elucidate the clinicopathological significance and prognostic value of level in GC. We used sequencing data from the Cancer Genome Atlas (TCGA) database to analyze expression in GC by UALCAN database and Gene Expression Profiling Interactive Analysis tools (GEPIA). expression level in 12 pairs of fresh GC tissues and adjacent nontumorous tissues was detected by quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR) and Western blot (WB) assays. Immunohistochemical (IHC) staining was used to detect TC2N protein expression in Paraffin-embedded tissues in our center. proliferation, migration and invasion assays were used to evaluate the effect of on functional capability of gastric cancer cells. LinkedOmics was used to identify gene expressions associated with . The mRNA and protein expression of in gastric cancer were both significantly higher than normal gastric mucosa. It was also elevated in gastric cancer cells compared with normal gastric epithelium cell. assays suggested that facilitated proliferation, migration and invasion of gastric cancer cells. Bioinformatic analysis showed a widespread impact of on the transcriptome and a strong interaction with tumor associated genes. We also found that was an independent prognostic factor for long-term survival in GC patients and its high expression was evidently associated with poor overall survival and recurrence-free survival. Our results show that high level of TC2N correlates with poor prognosis in patients with gastric cancer and promotes the development of gastric cancer. Thus, TC2N expression can serve as a prognostic biomarker for patients with gastric cancer.